SecurityPTN / Palatin Technologies, Inc. (696077403)
President and CEOSPANA CARL
IndustryPharmaceutical Preparations
Institutional Owners72
Institutional Shares30,187,787 - 15.19%
Common Shares Outstanding198,677,039 shares (as of 2018-03-31)
Institutional Value$ 29,125,000 USD

Institutional Stock Ownership and Shareholders()

PTN / Palatin Technologies, Inc. Institutional Ownership

Palatin Technologies, Inc. (AMEX:PTN) has 72 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 30,187,787 shares. Largest shareholders include Vanguard Group Inc, Acadian Asset Management Llc, Flynn James E, Renaissance Technologies LLC, Deutsche Bank Ag\, Alyeska Investment Group, L.P., Ajo, Lp, BlackRock Inc., Arrowstreet Capital, Limited Partnership, and BlackRock Institutional Trust Company, N.A..
Palatin Technologies, Inc. (AMEX:PTN) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ptn"><img src="https://images.fintel.io/us-ptn-so.png" alt="PTN / Palatin Technologies, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-14 13F-HR Crestwood Advisors LLC 25,000 25,000 0.00 21 27 28.57
2018-05-10 13F-HR JP Morgan Chase & Co 600 600 0.00 1 1 0.00
2018-04-18 13F-HR WealthTrust-Arizona, LLC 200 200 0.00 0 0
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 1,228 2,361 92.26 1 3 200.00
2018-05-01 13F-HR WealthTrust Axiom LLC 24,860 22,060 -11.26 21 24 14.29
2018-05-11 13F-HR Tibra Equities Europe Ltd 387,535 422
2018-04-30 13F-HR Certified Advisory Corp 500 500 0.00 0 0
2017-02-10 13F-HR BlackRock Advisors LLC 23,498 23,498 0.00 15 12 -20.00
2018-05-17 13F-HR McKinley Carter Wealth Services, Inc. 500 1
2018-05-11 13F-HR SEI INVESTMENTS CO 18,117 18,534 2.30 16 21 31.25
2018-05-08 13F-HR US BANCORP \DE\ 159,740 159,740 0.00 137 174 27.01
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 488,202 488,202 0.00 419 532 26.97
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 51,979 312,050 500.34 44 340 672.73
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 5,000 0 -100.00 4 0 -100.00
2018-02-15 13F-HR Bb&t Investment Services, Inc. 20 20 0.00 0 0
2018-05-11 13F-HR/A COMPTON CAPITAL MANAGEMENT INC /RI 13,000 20,000 53.85 11 22 100.00
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 1,040 1,080 3.85 1 1 0.00
2018-05-15 13F-HR BlueCrest Capital Management Ltd 23,260 25
2018-05-11 13F-HR Russell Investments Group, Ltd. 0 47,220 0 51
2018-05-14 13F-HR MORGAN STANLEY 0 313 0 0
2018-05-15 13F-HR Carnegie Capital Asset Management, LLC 30,000 30,000 0.00 27 38 40.74
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 272,717 246,887 -9.47 234 269 14.96
2018-05-14 13F-HR AJO, LP 1,242,316 1,354
2018-05-22 13F-HR MEMBERS Trust Co 13,150 13,150 0.00 11 14 27.27
2018-04-16 13F-HR Raymond James Financial Services Advisors, Inc. 14,815 14,815 0.00 13 16 23.08
2018-05-15 13F-HR National Asset Management, Inc. 38,000 38,000 0.00 33 42 27.27
2017-02-10 13F-HR BlackRock Fund Advisors 12,157 15,397 26.65 8 8 0.00
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 13,250 17,450 31.70 6 12 100.00
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 546,000 546,000 0.00 469 595 26.87
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 938,530 1,098,128 17.01 590 555 -5.93
2018-05-15 13F-HR JANE STREET GROUP, LLC 0 17,000 0 19
2018-05-15 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 219,795 240
2018-04-18 13F-HR Cordasco Financial Network 2,940 3
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 160,093 172,183 7.55 137 188 37.23
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 4,953 40,996 727.70 4 45 1,025.00
2018-04-24 13F-HR Baystate Wealth Management LLC 13,233 13,233 0.00 12 16 33.33
2018-05-09 13F-HR BlackRock Inc. 1,236,266 1,224,984 -0.91 1,062 1,335 25.71
2018-05-11 13F-HR GSA CAPITAL PARTNERS LLP 18,200 0 -100.00 16 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 75,307 173,790 130.78 64 189 195.31
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 839,777 1,015,697 20.95 721 1,106 53.40
2017-04-07 13F-HR CT Financial Advisors LLC 375 375 0.00 189 123 -34.92
2018-05-15 13F-HR FIFTH THIRD BANCORP 10,000 11
2018-05-15 13F-HR TWO SIGMA ADVISERS, LP 12,300 48,500 294.31 11 53 381.82
2018-05-15 13F-HR VANGUARD GROUP INC 7,565,490 7,581,555 0.21 6,498 8,264 27.18
2018-05-15 13F-HR Alyeska Investment Group, L.P. Call 1,538,462 1,538,462 0.00 1,321 1,677 26.95
2018-05-15 13F-HR GUGGENHEIM CAPITAL LLC 43,115 43,379 0.61 37 47 27.03
2018-05-15 13F-HR Cubist Systematic Strategies, LLC 55,096 60
2017-01-13 13F-HR MetLife Securities, Inc 200 0
2018-05-15 13F-HR Bank of New York Mellon Corp 125,929 140,856 11.85 108 154 42.59
2018-05-17 13F-HR M Holdings Securities, Inc. 11,230 12,289 9.43 10 13 30.00
2018-05-15 13F-HR LPL Financial LLC 28,000 28,000 0.00 24 31 29.17
2018-04-24 13F-HR Rehmann Capital Advisory Group 12,000 0 -100.00 10 0 -100.00
2018-05-09 13F-HR Pictet & Cie (Europe) SA 62,000 62,000 0.00 53 68 28.30
2018-04-20 13F-HR FIRST MANHATTAN CO 50 50 0.00 0 0
2018-05-14 13F-HR AMERIPRISE FINANCIAL INC 12,500 0 -100.00 11 0 -100.00
2018-05-11 13F-HR MACQUARIE GROUP LTD 473,306 1,046,906 121.19 407 1,141 180.34
2018-05-14 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 173,873 1,200,914 590.68 149 1,309 778.52
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 0 39,524 0 43
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 5,042 19,042 277.67 4 21 425.00
2018-05-15 13F-HR Gotham Asset Management, LLC 18,381 45,903 149.73 16 50 212.50
2018-05-14 13F-HR Renaissance Technologies LLC 1,694,865 2,745,729 62.00 1,456 2,993 105.56
2018-05-14 13F-HR Virtu Financial LLC 632,045 153,354 -75.74 543 167 -69.24
2018-05-15 13F-HR Advisor Group, Inc. 1,765 2,765 56.66 1 3 200.00
2018-05-09 13F-HR PALISADE CAPITAL MANAGEMENT LLC/NJ 19,010 19,010 0.00 16 21 31.25
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 49,853 54
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 12,742 582,644 4,472.63 11 635 5,672.73
2018-05-15 13F-HR Highlander Capital Management, LLC 50,000 0 -100.00 43 0 -100.00
2017-02-14 SC 13G/A Flynn James E 4,733,815 2,967,391 -37.32
2018-05-14 13F-HR Commonwealth Equity Services, Llc. 19,880 21,880 10.06 17 23 35.29
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 1,249,283 3,315,152 165.36 1,075 3,613 236.09
2018-05-09 13F-HR NORTHERN TRUST CORP 271,926 333,277 22.56 233 363 55.79
2018-05-15 13F-HR SALEM INVESTMENT COUNSELORS INC 150 0 -100.00 0 0
2018-05-11 13F-HR CITADEL ADVISORS LLC 173,790 189
2018-05-15 13F-HR DEUTSCHE BANK AG\ 1,366,975 1,578,404 15.47 1,174 1,720 46.51
2018-05-15 13F-HR STATE STREET CORP 17,409 68,539 293.70 14 75 435.71
2018-05-14 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 23,498 26
2018-05-10 13F-HR WASHINGTON TRUST Co 10,000 10,000 0.00 9 11 22.22
2018-05-15 13F-HR UBS Group AG 25,252 4,078 -83.85 22 4 -81.82
2018-05-15 13F-HR BARCLAYS PLC 144,500 128,400 -11.14 124 140 12.90
PTN : Palatin Technologies Stock Analysis and Research Report

2017-10-26 - Asif

Palatin Technologie is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (“HSDD”), which is a type of female sexual dysfunction (“FSD”), defined as low desire with associated distress. In addition, Palatin has drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The following drug development programs are actively under development: Bremelanotide, an as-needed subcutaneous injectable product for the treatment of HSDD in premenopausal women. Bremelanotide is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulat...

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

Related News Stories

The Women’s Libido Pill Is Back, and So Is the Controversy - Bloomberg

2018-06-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (76-2)

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors. (299-3)

Palatin shares surge 9% premarket after FDA accepts for review treatment for HSDD - MarketWatch

2018-06-04 marketwatch
Palatin Technologies Inc. shares PTN, +7.21% surged 9% in premarket trade Monday, after the company said the U.S. Food and Drug Administration has accepted the new drug application for bremelanotide, a treatment for female sexual desire disorder. The NDA was filed by Amag Pharmaceuticals Inc. AMAG, +0.61% Palatin's exclusive North America licensee, in March. The goal date for completion of the review is March 23, 2019. (59-0)

Palatin Technologies' (PTN) CEO Carl Spana on Q3 2018 Results - Earnings Call Transcript

2018-05-15 seekingalpha
Good morning, ladies and gentlemen, and welcome to the Palatin Technologies Third Quarter Fiscal Year 2018 Results Conference Call. As a reminder, this conference is being recorded. (59-1)

BRIEF-Palatin Technologies Says Entered Into An Equity Distribution Agreement

2018-04-20 reuters
* PALATIN TECHNOLOGIES INC - CO MAY SELL SHARES OF STOCK, PAR VALUE $0.01 PER SHARE, HAVING AN OFFERING PRICE OF UP TO $25 MILLION Source : bit.ly/2HDue9S Further company coverage: ([email protected]) (48-17)

CUSIP: 696077403